New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Vivani Medical, Inc.

Contributing Author

Recent Articles by Vivani Medical, Inc.

Sep-17	Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders VANI GlobeNewswire
Sep-04	Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management VANI GlobeNewswire
Aug-20	Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 VANI GlobeNewswire
Aug-13	Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results VANI GlobeNewswire
Aug-05	Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115 VANI GlobeNewswire
Jun-11	Vivani Medical Appoints Anthony Baldor as Chief Financial Officer VANI GlobeNewswire
Jun-10	Vivani Medical to Present at the 2025 BIO International Convention VANI GlobeNewswire
May-29	Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders VANI GlobeNewswire
May-13	Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results VANI GlobeNewswire
May-07	Vivani Medical to Present at the American Association of Pharmaceutical Scientists' "Beyond GLP1s: Where the Science will Take Business Next" Virtual Workshop VANI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.